Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/14/2025 | $80.00 | Equal Weight | Wells Fargo |
1/6/2025 | $69.00 → $84.00 | Underperform → Buy | BofA Securities |
12/4/2024 | $75.00 | Neutral | Mizuho |
7/22/2024 | $81.00 → $92.00 | Neutral → Outperform | Robert W. Baird |
2/26/2024 | $78.00 | Market Perform | Leerink Partners |
12/12/2023 | $71.00 → $82.00 | Neutral → Overweight | JP Morgan |
11/10/2023 | $70.00 | Hold → Buy | Stifel |
8/8/2022 | $80.00 | Sell → Neutral | UBS |
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
4 - HENRY SCHEIN INC (0001000228) (Issuer)
Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in June: Jefferies Global Healthcare Conference at the Marriott Marquis hotel, New York City, on June 4, at 12:50 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and technology. With ap
Patient experience is the differentiator – The Catalyst Index reveals how top practices reduce friction to retain and engage patients Henry Schein One today announced the launch of The 2025 Catalyst Index, its exclusive report offering dental practices an unparalleled view into the strategies transforming performance across the industry. Built on years of trusted benchmarking and informed by Henry Schein One's most connected platform, the fourth annual report, The Catalyst Index, raises the bar by revealing the specific actions that distinguish the top 10% of DSOs and private practices. "We're at a turning point in dentistry," said Dr. Ryan Hungate, Chief Clinical and Strategy Officer, He
Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt
11-K - HENRY SCHEIN INC (0001000228) (Filer)
8-K - HENRY SCHEIN INC (0001000228) (Filer)
SD - HENRY SCHEIN INC (0001000228) (Filer)
Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00
BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously
Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00